12:00 AM
 | 
Sep 22, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anagrelide CR: Phase II started

Galena began an open-label, U.S. Phase II trial to evaluate oral GALE-401 twice daily for >=24 weeks in about 20 patients with elevated platelet counts secondary to essential thrombocythemia and other myeloproliferative neoplasms. Patients will...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >